Background erenumab was safe and effective in clinical trials for the prevention of migraine.
However, real-life data are still lacking. Here we report the clinical experience from an Italian …

Objective To evaluate the long‐term effectiveness, safety, and tolerability of erenumab in a
real‐world migraine population, looking for putative predictors of responsiveness …

Objective To assess the effectiveness, safety, and tolerability of erenumab in a real‐life
migraine population, while trying to identify responsiveness predictors. Background …

Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …

Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …

Background Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide
(CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing …

Background Erenumab, a calcitonin gene‐related peptide (CGRP) receptor monoclonal
antibody, has been well tolerated with good efficacy for the preventive treatment of episodic …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Objective EMPOwER, a double-blind, randomised, phase 3 study, evaluated the efficacy
and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and …